COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Open Label Seroquel (Quetiapine) Study for Treatment Resistant Functional Bowel Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00617396
Recruitment Status : Completed
First Posted : February 18, 2008
Results First Posted : March 21, 2014
Last Update Posted : September 15, 2017
Information provided by (Responsible Party):
University of North Carolina, Chapel Hill

Brief Summary:

Purpose: We are proposing to examine, via open label trial, the use of Seroquel® for patients with moderate to severe functional bowel symptoms who are not receiving adequate relief from their symptoms on their present regimen of SNRI or TCA antidepressant agents.

Participants: Primary eligibility will be determined of patients at The UNC Center for Functional GI & Motility Disorders Clinic who score in the moderate to severe range on the Functional Bowel Disorders Severity Index (FBDSI ≥ 37) who have failed or have incomplete treatment responses of medications including at least one prior trial of antidepressant medication.

Procedures (methods): We will monitor several patient and symptom related outcomes, as well as evaluate health related quality of life, psychological distress and related psychosocial measures to determine if the addition of Seroquel® over and above the use of an antidepressant improves clinical response based on an adequate relief measure as well as selected secondary outcomes. We will also determine when treatment benefit is related to effects on pain, the associated psychological co-morbidities seen in this population, or both factors.

Condition or disease Intervention/treatment Phase
Functional Bowel Disorders Drug: Quetiapine (50 mg/day-100mg/day) Not Applicable

Detailed Description:
The UNC Center for Functional GI & Motility Disorders Clinic frequently receives referrals for patients with chronic and treatment refractory symptoms of abdominal pain and bowel dysfunction. Many of these patients are diagnosed with irritable bowel syndrome, painful functional constipation or functional abdominal pain syndrome using Rome III criteria. The presenting symptoms of the referral population are frequently in the severe range, with patients having intensely painful symptoms, Axis I and Axis II co-morbidities, and impaired health related quality of life. Failure of multiple standard treatment attempts prior to referral is customary for patients seen in our clinic. Additionally, a greater number of patients only experience a partial response to standard treatment. We are therefore attempting to address these patients utilizing novel treatment strategies such as we propose here.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label Study of Seroquel SR® (Quetiapine) for the Treatment of Refractory and Treatment Resistant Functional Bowel Disorders
Study Start Date : February 2008
Actual Primary Completion Date : January 2012
Actual Study Completion Date : May 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Quetiapine treatment group
All subjects will receive seroquel treatment for 8 weeks. Seroquel is the intervention.
Drug: Quetiapine (50 mg/day-100mg/day)
Subject begin with a dose quetiapine of 50mg for 2 weeks, increasing to 100mgs for the remainder of the study. (8 weeks total)
Other Name: Seroquel

Primary Outcome Measures :
  1. Adequate Relief in Pain Score During Treatment [ Time Frame: 8 weeks ]
    Biweekly relief in pain Biweekly subjects were asked whether they had adequate relief of pain. It was binary questionnaire i.e.- " Did you have adequate relief of pain in last two weeks? 1) yes 2) no The measure is percentage of subjects who said yes who had adequate relief of pain.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The subject has been diagnosed with a painful functional bowel disorder lasting longer than six months
  • The subject achieves a score greater than 37 on the Functional Bowel Disorders Severity Index
  • Four weeks on anti-depressant medications did not lead to adequate relief of the GI symptoms

Exclusion Criteria:

  • Patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others
  • Known intolerance or lack of response to Seroquel as judged by the investigator
  • Use of prohibited medicationsMedical conditions that would affect absorption, distribution, metabolism, or excretion of study treatment
  • Unstable or inadequately treated medical
  • An absolute neutrophil count (ANC) of ≤1.5 X 109 per liter
  • Subject is pregnant or breastfeeding.
  • Subject is taking other medication thought to directly affect gut function via the 5HT method of action (Tegaserod)
  • Known hypersensitivity to duloxetine or any of the inactive ingredients in duloxetine
  • Any patient taking Monoamine Oxidase Inhibitors
  • Patient with uncontrolled narrow-angle glaucoma

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00617396

Layout table for location information
United States, North Carolina
UNC Center for Functional GI & Motility Disorders
Chapel Hill, North Carolina, United States, 27599
Sponsors and Collaborators
University of North Carolina, Chapel Hill
Layout table for investigator information
Principal Investigator: Douglas A Drossman, MD UNC Chapel Hill
Layout table for additonal information
Responsible Party: University of North Carolina, Chapel Hill Identifier: NCT00617396    
Other Study ID Numbers: IRUSQUET0448
First Posted: February 18, 2008    Key Record Dates
Results First Posted: March 21, 2014
Last Update Posted: September 15, 2017
Last Verified: February 2014
Keywords provided by University of North Carolina, Chapel Hill:
Irritable Bowel Syndrome
Abdominal Pain
Additional relevant MeSH terms:
Layout table for MeSH terms
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Quetiapine Fumarate
Antidepressive Agents
Psychotropic Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs